James E. Radford - Concepedia

Author

James E. Radford

Wake Forest University

Also Known As

J E Radford, J. E. Radford, JAMES E. RADFORD, James E Radford, James E. Radford

Publications

801

Citations

H-Index

Concepts

All Affiliations

Wake Forest University University of Iowa

About

James E. Radford is an author at Wake Forest University specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	520
2	Health Sciences	3	3	116
3	Pathology	2	2	467
4	Cellular Therapies	1	1	12
5	Immunology	1	1	12

James E. Radford

Publications

698

Citations

H-Index

Page 1

	Year	Citations
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Charles E. Geyer, Judy E. Garber, Richard D. Gelber, Annals of Oncology Breast OncologyOverall SurvivalMedicinePathologyGermline Pathogenic Variants	2022	404
Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. Elisabetta Abruzzese, James E. Radford, Jeffrey S. Miller, PubMed	1999	100
Adult acute lymphoblastic leukemia: results of the Iowa HOP-L protocol. James E. Radford, C. Patrick Burns, Mary Jones, Journal of Clinical Oncology Mixed-phenotype Acute LeukemiaPathologyImmunotherapyMyeloid NeoplasiaHematological Malignancy	1989	63
Randomized Trial to Assess the Impact of Venlafaxine and Soy Protein on Hot Flashes and Quality of Life in Men With Prostate Cancer Mara Z. Vitolins, Leah Griffin, W. Vic Tomlinson, Journal of Clinical Oncology	2013	59
Phase II Trial of Paclitaxel–Topotecan–Etoposide Followed by Consolidation Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer: CALGB 30002 Antonius A. Miller, Xiaofei F. Wang, Jeffrey A. Bogart, Journal of Thoracic Oncology Calgb 30002MedicineMetronomic TherapyConsolidation ChemoradiotherapyPaclitaxel–topotecan–etoposide Followed	2007	41
The Human Leukocyte Antigen A2 Interferon-stimulated Response Element Consensus Sequence Binds a Nuclear Factor Required for Constitutive Expression Jeffrey F. Waring, James E. Radford, Linda J. Burns, Journal of Biological Chemistry	1995	19
Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation Hakan Kaya, Yi‐Kong Keung, Douglas Case, Biology of Blood and Marrow Transplantation Cell TherapyImmunologyAutologous TransplantationImmunotherapyHematological Malignancy	2002	12

Page 1